Sopharma AD reports sale of treasury shares on Bulgarian Stock Exchange

Ognyan Ivanov Donev Chairman of the Board of Directors and Executive Director Sopharma AD
Ognyan Ivanov Donev Chairman of the Board of Directors and Executive Director - Sopharma AD
0Comments

Sopharma AD has announced the sale of 7,450 treasury shares on August 14, 2025. The transaction took place on the Bulgarian Stock Exchange at an average price of BGN 2.45 per share, resulting in a total value of BGN 18,252.50.

Following this sale, Sopharma AD holds 21,372,104 treasury shares, which amounts to 3.96% of its total share capital.

“Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on August14, 2025 the Company sold7 450(seven thousand four hundred and fifty) treasury shares representing 0.001% of the share capital of the Company, at a total value of BGN 18 252.50on the Bulgarian Stock Exchange, the average price per share was BGN 2.45.”

The company made this disclosure in line with Article 17 of Regulation (EU) No 596/2014 from the European Parliament and Council.

The update reflects changes in Sopharma AD’s ownership structure as it continues to manage its treasury stock.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.